title: Hemorrhagic cystitis in a patient receiving gemtuzumab ozogamicin for relapsed acute promyelocytic leukemia after cord blood transplantation.
authors.forename: Akihide
authors.initials: A
authors.lastname: Yoshimi
authors.forename: Takashi
authors.initials: T
authors.lastname: Asai
authors.forename: Akira
authors.initials: A
authors.lastname: Hangaishi
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takahashi
authors.forename: Shigeru
authors.initials: S
authors.lastname: Chiba
authors.forename: Mineo
authors.initials: M
authors.lastname: Kurokawa
mesh_terms: D000617:Aminoglycosides / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D036101:Cord Blood Stem Cell Transplantation; D003556:Cystitis / Q000139:chemically induced* / Q000473:pathology; D000079982:Gemtuzumab; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab